Akers Biosciences Inc

Q: Jun 30 2026

Q: Mar 31 2026

FY: Dec 31 2025

FY: Dec 31 2025

FY: Dec 31 2025

Q: Sep 30 2025

Q: Sep 30 2025

Q: Jun 30 2025

Q: Jun 30 2025

Q: Mar 31 2025

FY: Dec 31 2024

FY: Dec 31 2024

Q: Sep 30 2024

Q: Jun 30 2024

Q: Jun 30 2024

Q: Mar 31 2024

FY: Dec 31 2023

Q: Sep 30 2023

Q: Jun 30 2023

Q: Mar 31 2023

Entry into a Material Definitive Agreement

Termination of a Material Definitive Agreement

Termination of a Material Definitive Agreement

Changes in Registrant's Certifying Accountant

Entry into a Material Definitive Agreement

Entry into a Material Definitive Agreement

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Entry into a Material Definitive Agreement

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Entry into a Material Definitive Agreement

Financial Statements and Exhibits

Entry into a Material Definitive Agreement

Material Modifications to Rights of Security Holders

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Shareholder Nominations Pursuant to Exchange Act Rule 14a-11

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Regulation FD Disclosure

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

1.01,3.02,8.01,9.01

Notice of Effectiveness

Registration statement under Securities Act of 1933

Prospectus Supplement for Primary Offering

Notice of Effectiveness

Registration statement under Securities Act of 1933

Rule 506(b) provides a "safer harbor" for a private offering

Prospectus Supplement for Primary Offering

Notice of Effectiveness

Registration statement under Securities Act of 1933 (amendment)

Registration statement under Securities Act of 1933

06b

06b

Prospectus Supplement for Primary Offering

06b

Prospectus Supplement for Primary Offering

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Prospectus Supplement for Primary Offering

Notice of Effectiveness

Registration statement under Securities Act of 1933 (amendment)

Written communication about a business combination transaction (Rule 425)

Definitive Proxy Statement

Preliminary Proxy Statement

Required Information in Proxy Statement

No description available

Definitive Proxy Statement

Preliminary Proxy Statement

Definitive Proxy Statement

Definitive Proxy Statement

Preliminary Proxy Statement

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Preliminary Proxy Statement

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Preliminary Proxy Statement

Definitive Proxy Statement

Additional Information for Proxy Statement/ Votes

Additional Information for Proxy Statement/ Votes

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Silverman Joshua

Silverman Joshua

Ehrlichman Yossef

Fagan Charles Todd

Voss Chelsea Sierra

Voss Chelsea Sierra

White Billy Joe

Bernstein Bruce

Friscia Stephen

Glass Mitchell

Silverman Joshua

Voss Chelsea Sierra

Voss Chelsea Sierra

PharmaCyte Biotech, Inc.

PharmaCyte Biotech, Inc.

White Billy Joe

Glass Mitchell

RAUCH GARY M

Silverman Joshua

Friscia Stephen

Correspondence with the SEC

Letter from the SEC

Draft registration statement (confidential submission)

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

Annual Report Scanned (Paper)

Annual Report Scanned (Paper)

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

Annual Report Scanned (Paper)

Correspondence with the SEC

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC